These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 7719272)

  • 41. Delivery systems to increase the selectivity of antibiotics in phagocytic cells.
    Briones E; Colino CI; Lanao JM
    J Control Release; 2008 Feb; 125(3):210-27. PubMed ID: 18077047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.
    Gregoriadis G; Florence AT
    Drugs; 1993 Jan; 45(1):15-28. PubMed ID: 7680982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci.
    Bakker-Woudenberg IA
    Int J Antimicrob Agents; 2002 Apr; 19(4):299-311. PubMed ID: 11978501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Particulate delivery systems for vaccines: what can we expect?
    Bramwell VW; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focused Insights into Liposomal Nanotherapeutics for Antimicrobial Treatment.
    Jani K; Mehta S; Patel R; Prajapati B; Patel G
    Curr Med Chem; 2024 Oct; ():. PubMed ID: 39421994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.
    van Slooten ML; Storm G; Zoephel A; Küpcü Z; Boerman O; Crommelin DJ; Wagner E; Kircheis R
    Pharm Res; 2000 Jan; 17(1):42-8. PubMed ID: 10714607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.
    Muderhwa JM; Matyas GR; Spitler LE; Alving CR
    J Pharm Sci; 1999 Dec; 88(12):1332-9. PubMed ID: 10585231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simple nanoliposomes encapsulating
    Bo R; Sun Y; Zhou S; Ou N; Gu P; Liu Z; Hu Y; Liu J; Wang D
    Int J Nanomedicine; 2017; 12():6289-6301. PubMed ID: 28894367
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages.
    van Rooijen N
    J Drug Target; 2008 Aug; 16(7):529-34. PubMed ID: 18686122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liposomes as delivery systems for antibiotics.
    Drulis-Kawa Z; Dorotkiewicz-Jach A
    Int J Pharm; 2010 Mar; 387(1-2):187-98. PubMed ID: 19969054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products.
    Mohammed AR; Bramwell VW; Coombes AG; Perrie Y
    Methods; 2006 Sep; 40(1):30-8. PubMed ID: 16997711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers.
    Ranade VV
    J Clin Pharmacol; 1989 Aug; 29(8):685-94. PubMed ID: 2674208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Various aspects of the use of liposomes in the diagnosis, prophylaxis and treatment of infectious diseases].
    Zakrevskiĭ VI
    Mol Gen Mikrobiol Virusol; 1985 Jan; (1):3-9. PubMed ID: 3939569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colloidal drug delivery systems in vaccine delivery.
    Beg S; Samad A; Nazish I; Sultana R; Rahman M; Ahmad MZ; Akbar M
    Curr Drug Targets; 2013 Jan; 14(1):123-37. PubMed ID: 23072326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
    Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
    Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
    Alving CR
    Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes.
    Peer D; Margalit R
    Arch Biochem Biophys; 2000 Nov; 383(2):185-90. PubMed ID: 11185552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liposomes for Antibiotic Encapsulation and Delivery.
    Gonzalez Gomez A; Hosseinidoust Z
    ACS Infect Dis; 2020 May; 6(5):896-908. PubMed ID: 32208673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.
    Nikoofal-Sahlabadi S; Matbou Riahi M; Sadri K; Badiee A; Nikpoor AR; Jaafari MR
    Eur J Pharm Sci; 2018 Jul; 119():159-170. PubMed ID: 29660463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.